| Treatment | Dosing | ||||
---|---|---|---|---|---|---|
 | n evaluated | N (%) | n evaluated | Partner drug dose median (Range) | Artemisinin derivative dose median (Range) | Underdosed n (%) |
AL | 48840 | 13217 (27 %) | 13086 | 68.6 (8.9–144.0) | 11.4 (1.5–24.0) | 1008 (8.3 %) |
AS-AQ | 48840 | 8488 (17 %) | 8395 | 31.9 (10.0–91.8) | 12.4 (4.0–52.6) |  |
AS-AQ formulation: | Â | Â | Â | Â | Â | Â |
 Co-blistered nFDC | 8488 | 573 (7 %) | 573 | 37.4 (14.8–91.8) | 13.5 (4.8–30.0) |  |
 FDC | 8488 | 4278 (50 %) | 4262 | 32.4 (14.5–81.0) | 12.0 (5.4–30.0) | 2 (0.1 %) |
 nFDC | 8488 | 3637 (43 %) | 3560 | 30.1 (10.0–60.0) | 12.5 (4.0–52.6) |  |
AS-MQ | 48840 | 5198 (11 %) | 4535 | 25.0 (4.2–85.0) | 12.0 (2.3–62.1) | 38 (0.8 %) |
DP | 48840 | 6453 (13 %) | 6315 | 53.3 (14.5–182.9) | 6.7 (1.8–22.9) | 1488 (23.6 %) |
Other, including non-ACT | 48840 | 15484 (32 %) | Â | Â | Â | Â |